PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-22.30%
Negative net income growth while AXSM stands at 35.33%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
24.17%
D&A growth well above AXSM's 5.89%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
100.00%
Some yoy growth while AXSM is negative at -513.78%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
-9.33%
Both cut yoy SBC, with AXSM at -0.44%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
-80.33%
Negative yoy working capital usage while AXSM is 182.94%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-46.04%
Both negative yoy AP, with AXSM at -10.83%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-249.09%
Negative yoy usage while AXSM is 55.49%. Joel Greenblatt would see a short-term advantage in freeing up capital unless competitor invests effectively in these lines.
-101.42%
Both negative yoy, with AXSM at -7.79%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
-72.30%
Both yoy CFO lines are negative, with AXSM at -6.19%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-455.28%
Both yoy lines negative, with AXSM at -1457500.00%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We have some outflow growth while AXSM is negative at -47.26%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
-427.62%
Both yoy lines negative, with AXSM at -1457500.00%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
53916.27%
We slightly raise equity while AXSM is negative at -98.43%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.